Q3 2026 Sakar Healthcare Ltd Earnings Call Transcript
Key Points
- Sakar Healthcare Ltd (NSE:SAKAR) reported a robust 62% year-on-year growth in revenue for Q3 FY26, reaching INR7,034 lakhs.
- The company's oncology vertical demonstrated strong traction, with significant contributions to revenue growth and profitability.
- The EU-GMP approved oncology facility at Bavla has gained strategic relevance, enabling Sakar Healthcare to serve stringent regulated markets.
- Profit after tax for Q3 FY26 increased by 126% year-on-year, supported by operating leverage and a better product mix.
- The company has successfully submitted 102 oncology dossiers globally, with 11 receiving marketing authorizations, enhancing its market presence.
- The company faces challenges in regulatory approvals, which can impact the timely commercialization of products.
- Employee costs have increased, with a sequential rise from 8.3% to 9.9% of revenue, potentially affecting margins.
- The tax rate for the quarter was lower due to MAT credit utilization, which may not be sustainable in the long term.
- The company is heavily reliant on the oncology segment for growth, which could pose risks if market conditions change.
- There is uncertainty regarding the timelines for marketing authorizations in Western Europe, which could delay revenue realization.
Ladies and gentlemen, good day and welcome to the Sakar Healthcare Limited Q3 FY26 earnings conference call hosted by MFG in time. (Operator Instruction) I now hand the conference over to Mr. Nikunj Seth from MUFG.
Thank you and over to you, Mr. Nikunj.
Thank you for your call.
Welcome to Sakar Healthcare Q3 F5 26 earnings call.
Today on the call we have Mr. Bikramjit Ghosh; Vice President, Strategy and Business Development, Mr. Dharmesh Thaker; CFO, Mr. Bharat Soni; Company secretary, and Ms. Pushpa Ponmany; manager.
Before we proceed with the call, I would like to give a small disclaimer that the call may contain certain forward-looking statements which are based on the business opinions and expectations of the company as of today. A detailed disclaimer has been given in the company's investor presentation which was uploaded on the stock exchange. Now I would like to hand over the call to Miss Pushpa over to you.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
